Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.826
-0.010 (-1.14%)
Mar 9, 2026, 2:36 PM EDT - Market open
Company Description
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products.
Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS.
Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Citius Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Leonard Mazur |
Contact Details
Address: 11 Commerce Drive, First Floor Cranford, New Jersey 07016 United States | |
| Phone | 908 967 6677 |
| Website | citiuspharma.com |
Stock Details
| Ticker Symbol | CTXR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001506251 |
| CUSIP Number | 17322U207 |
| ISIN Number | US17322U3068 |
| Employer ID | 27-3425913 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leonard L. Mazur | Co-Founder, Chief Executive Officer, Chairman and Secretary |
| Myron Z. Holubiak | Co-Founder and Executive Vice Chairman |
| Dr. Myron S. Czuczman M.D. | Executive Vice President and Chief Medical Officer |
| Jaime Bartushak | Chief Business Officer and Chief Financial Officer |
| Gary F. Talarico | Executive Vice President of Operations |
| Ilanit Allen | Vice President of Investor Relations and Corporate Communications |
| Dr. Alan Lader Ph.D. | Senior Vice President and Head of Clinical Operations and Quality Assurance |
| Dhananjay G. Wadekar | Senior Vice President of Business Strategy |
| Kelly Creighton Ph.D. | Executive Vice President of Chemistry, Manufacturing and Controls |
| Nikolas Burlew | Executive Vice President of Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 4, 2026 | 8-K | Current Report |
| Feb 24, 2026 | ARS | Filing |
| Feb 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 24, 2026 | DEF 14A | Other definitive proxy statements |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | 8-K | Current Report |
| Feb 13, 2026 | 10-Q | Quarterly Report |
| Jan 28, 2026 | 10-K/A | [Amend] Annual report |
| Dec 23, 2025 | 8-K | Current Report |
| Dec 23, 2025 | 10-K | Annual Report |